Nanotechnology Now - Press Release: "Potential for New Nanoparticle-Based Cancer Detection"

Home > Press > Potential for New Nanoparticle-Based Cancer Detection

Abstract:
Recent studies support the idea that the standard methods of screening men for prostate cancer leave much to be desired, particularly in terms of their inability to have much effect on prostate cancer survival. Now, a team of investigators at the University of Missouri School of Medicine have created a targeted gold nanoparticle that appears to offer a more sensitive and accurate method for detecting early stage prostate cancer. These nanoparticles may also be useful for detecting lung and breast cancers, too.

Potential for New Nanoparticle-Based Cancer Detection

Bethesda, MD | Posted on May 22nd, 2010

The investigators, led by Raghuraman Kannan and Kattesh Katti, published the results of their studies in the Proceedings of the National Academy of Sciences. Dr. Katti is the principal investigator of a National Cancer Institute Cancer Nanotechnology Platform Partnership.

Drs. Kannan and Katti and their colleagues created their potential imaging agent by coating gold nanoparticles with bombesin, also known as Gastrin Release Peptide (GRP), a naturally occurring molecule that binds to a specific receptor that is abundant on prostate, breast, and small cell lung cancer cells. To do so, they had to develop new synthetic methods for linking this peptide, as well as other related peptides, to the gold nanoparticles.

With the nanoparticles in hand, the research team used them to image prostate tumors growing in mice. These experiments demonstrated that the nanoparticles were very specific at binding to prostate tumors and that this binding enabled the tumors to be spotted easily using computed tomography x-ray imaging. Moreover, tumors took up approximately 10 times more of the targeted nanoparticles than bombesin linked directly to the radioactive element technetium, a construct now in clinical trials as an imaging agent. These experiments also showed that injecting the nanoparticles into the peritoneal cavity produced better results than when the nanoparticles were injected directly into the blood stream, in large part because fewer nanoparticles became trapped in the liver and spleen.

This work, which is detailed in a paper titled, "Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity," was supported in part by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. An abstract of this paper is available at the journal's Web site.

####

About NCI Alliance for Nanotechnology in Cancer
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: